AMU, AP-HM, CIML, INNATE PHARMA
Marseille Immunopole is born from the will of all partners to do even better and progress faster, and thus allow patients always to keep one step ahead of the disease.
At the end of 2013, Science Magazine designated immunotherapy as the major medical breakthrough of the year. Since then, the success of this new anti-cancer weapon has not been contradicted and tomorrow patients with inflammatory diseases should, in turn, benefit from this approach.
Today, our city is at the forefront of this revolution. Together, Marseille researchers, physicians and industry leaders have contributed and still contribute to the discovery, development and clinical evaluation of immunotherapy antibodies. They also develop diagnostic tools that should allow customisation of these drugs and an approach that many consider the next frontier of immunotherapy: cell therapies.
With my colleagues, I have already participated in the first part of this adventure: CIML contributed to NK immunotherapy developed by Innate Pharma, I myself cofounded the company in 1999 and created a laboratory at the Conception Hospital dedicated to the exploration of these lymphocytes. Lastly, with other immunology teachers of Aix-Marseille University, we also provide research, clinics and industry with new talents.
Marseille Immunopole is born from the will of all partners to do even better and progress faster, and thus allow patients always to keep one step ahead of the disease.#clinique #industrie #recherche
By creating this super innovation centre "outside the walls", which is Marseille Immunopole, we leverage our capabilities to ensure better and faster innovation.
The laboratory's mission therefore reflects that of the Marseille Immunopôle: to lead the development of these innovations, from the initial discovery to the proof of concept in clinical setting.
“Our immunotherapy antibodies are positioned at the crossroads of two immunology fields with high potential: the g9d2 T cells and a novel superfamily of immunomodulators, butyrophilins”
Thanks to this unprecedented alliance of researchers, clinicians, technological platforms and industrials we should be able to quickly do much better